Evidence map›Paper›PMID 36675491›Full record

ArticleJournal of clinical medicine2023

PFC@O

Zhou Lan, Ke-Long Zou, Hao Cui, Hao Chen, Yu-Yue Zhao, Guang-Tao Yu

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Effects of macrophages in OSCC progression.Frontiers in immunology · 2024
    Review
  3. Review
  4. The Role of IL-17 in the Pathogenesis of Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Zhou LanStomatological Hospital, Southern Medical University, Guangzhou 510280, China.
Ke-Long ZouStomatological Hospital, Southern Medical University, Guangzhou 510280, China.
Hao CuiStomatological Hospital, Southern Medical University, Guangzhou 510280, China.
Hao ChenStomatological Hospital, Southern Medical University, Guangzhou 510280, China.
Yu-Yue ZhaoStomatological Hospital, Southern Medical University, Guangzhou 510280, China.
Guang-Tao YuStomatological Hospital, Southern Medical University, Guangzhou 510280, China.ORCID 0000-0003-1642-3924
Southern Medical University · CN

Funding

Guangdong Basic and Applied Basic Research Foundation 2020A1515110719Guangzhou Basic and Applied Basic Research Foundation 202102020687Medical Research Fund of Guangdong Province No. B2020081National Natural Science Foundation of China 82103404Southern Medical University Excellent Youth Scholars Training Program 2020YQPY008Stomatological Hospital of Southern Medical University Startup Funds No. PY2019026Stomatological Hospital of Southern Medical University Startup Funds No. PY2020001
6 · The paper itself

Abstract

As a typical hallmark of solid tumors, hypoxia affects the effects of tumor radiotherapy, chemotherapy, and photodynamic therapy. Therefore, targeting the hypoxic tumor microenvironment (TME) is a promising treatment strategy for cancer therapy. Here, we prepared an Albumin Human Serum (HSA)-coated perfluorocarbon (PFC) carrying oxygen (PFC@O

Indexed as

HIF-1αhypoxiaoral squamous cell carcinomaperfluorocarbonstumor microenvironment

Identifiers

PMID36675491
PMCPMC9862098
OpenAlexW4315648016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.